Facebook
Twitter
LinkedIn
ForwardOligometastatic Breast Cancer: Considering Patients One by One
SBRT for oligometastatic disease of mixed histologies has been shown to improve progression-free and even overall survival. A large cooperative group study recently demonstrated that there was no overall survival advantage seen when constrained to breast cancer alone. With improving systemic therapy options, appropriate patient selection may be key when using metastasis directed therapy. It is important to understand the options and application backed by evidence to date when treating oligometastatic and oligoprogressive breast cancer.
This activity focuses on individualizing shared decision making between interdisciplinary teams and the patient. In a climate of rapidly changing systemic therapy, prolonged survival with metastatic disease, and conflicting messages from the literature, presenters help oncology teams understand the evidence to date and help demonstrate a variety of ways to apply new therapies for this patient population. Presenters discuss the data known to date and discuss application to varied cases. With radiation oncology and medical oncology presenting, different perspectives are shared when considering patient selection, therapeutic options, and sequencing of treatments for denovo oligometastatic, oligoprogressive, and oligopersistent disease. After presenters have completed, there is time for case discussions and/or panel Q&A.
Topics:
- Oligometastatic Breast Cancer: Systemic Therapy Considerations
Jairam Krishnamurthy, MD, FACP - Oligometastatic Breast Cancer: Patient Selection for Metastasis Directed Therapy
Steven J. Chmura, MD, PhD - A Primer on How-To: Spinal SBRT
Asal Shoushtari Rahimi, MD, MS - Q and A
Full Panel
This activity is available from May 28, 2024, through 11:59 p.m. Eastern time on May 27, 2026.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, diagnostic radiologists, dosimetrists, biologists, and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the current evidence for treating oligometastatic breast cancer.
- Analyze the conflicts in the evidence for and against metastasis directed therapy in oligometastatic breast cancer.
- Discuss the risks and benefits of varied approaches to specific case situations.
- Nathan Ronald Bennion, MD, is employed by the University of Nebraska Medical Center.
- Jairam Krishnamurthy, MD, FACP, is employed by the University of Nebraska Medical Center. Dr. Krishnamurthy serves on advisory boards for AstraZeneca and Gilead.
- Steven J. Chmura, MD, PhD, is employed by the University of Chicago. Dr. Chmura receives grant/research funding from BMS, Takeda, and Varian. Dr. Chmura receives honoraria from Genentc.
- Asal Shoushtari Rahimi, MD, MS, is employed by the University of Texas Southwestern Medical Center. Dr. Rahimi receives grant/research funding and honoraria from Accuray. Dr. Rahimi is a consultant with Hologic and serves on the advisory board of GE Health. Dr. Rahimi serves as a volunteer member of the NCCN Breast Cancer Risk Reduction Panel.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until May 27, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.